[Clinical aspects of the effectiveness of metformin therapy in combination with a low-calorie diet in patients with type 2 diabetes mellitus with various variants of the TCF7L2 gene polymorphism].

Autor:	Kondratyeva OV; Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation., Sharafetdinov KK; Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation.; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, 125993, Moscow, Russian Federation.; I.M. Sechenov First Moscow State Medical University of Ministry of Healthcare of the Russian Federation (Sechenov University), 119991, Moscow, Russian Federation., Plotnikova OA; Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation., Pilipenko VV; Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation., Alekseeva RI; Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation., Sorokina EY; Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation., Peskova EV; Federal Research Centre of Nutrition, Biotechnology and Food Safety, 109240, Moscow, Russian Federation.
Jazyk:	ruština
Zdroj:	Voprosy pitaniia [Vopr Pitan] 2022; Vol. 91 (2), pp. 5-14. Date of Electronic Publication: 2022 Mar 14.
DOI:	10.33029/0042-8833-2022-91-2-5-14
Abstrakt:	The TCF7L2 gene is one of the new markers associated with the development of type 2 diabetes mellitus (DM). Evaluation of the effect of TCF7L2 gene polymorphisms on the effectiveness of hypoglycemic therapy will allow an individual approach to the choice of methods for treating type 2 DM in their carriers. The aim of the research was to study the effect of carriage of TCF7L2 gene polymorphisms on glycemic control parameters in patients with type 2 DM receiving metformin glucose-lowering therapy in combination with a low-calorie version of the standard diet. Material and methods . The study included 55 patients with type 2 DM (mean age 59.9±6.9, BMI 44.3±8.2 kg/m 2 ) receiving metformin monotherapy at a dosage of 1500-2000 mg/day in combination with a low-calorie variant of the standard diet (1730±130 kcal/day). The frequency of occurrence of polymorphisms rs7903146/rs12255372 of the TCF7L2 gene was studied. The indicators of glycemic and metabolic control, anthropometric parameters and body composition were evaluated. Results . The frequency of occurrence of the T-allele of both single nucleotide polymorphisms rs7903146 and rs12255372 of the TCF7L2 gene among patients was 38.2%. Among carriers of the T-allele rs7903146 of the TCF7L2 gene, 72% of patients responded to therapy, showing a statistically significant decrease in the level of fasting glycemia by an average of 16.2±1.6% from the baseline, while among carriers of the CC genotype - 10.5±1.5% (p=0.017). There were no statistically significant changes in glycemic control indicators on hypoglycemic therapy during 7 months of observation, both in the group of T allele and CC genotype carriers. Conclusions s. An improvement in glycemic control was established in patients with type 2 DM among carriers of the T allele rs7903146 of the TCF7L2 gene during metformin therapy in combination with a low-calorie standard diet. The study of TCF7L2 gene polymorphism in combination with indicators of glucose metabolism makes it possible to predict the effectiveness of hypoglycemic therapy with great accuracy. Competing Interests: The authors declare no overt and potential conflict of interest related to the publication of this article. (Copyright© GEOTAR-Media Publishing Group.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu